問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberSLSG18-301
NCT Number(ClinicalTrials.gov Identfier)-
Active

2022-01-14 - 2027-05-31

Phase III

Recruiting4

ICD-10C92.01

Acute myeloblastic leukemia, in remission

ICD-10C92.41

Acute promyelocytic leukemia, in remission

ICD-10C92.51

Acute myelomonocytic leukemia, in remission

ICD-10C92.61

Acute myeloid leukemia with 11q23-abnormality in remission

ICD-10C92.A1

Acute myeloid leukemia with multilineage dysplasia, in remission

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9205.01

Acute myeloid leukemia, in remission

-

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/09/15

Investigators and Locations

Principal Investigator Hui-Hua Hsiao Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ya-Ting Hsu Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator PO-WEI LIAO

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 賴冠銘

Co-Principal Investigator

Principal Investigator HSIN-AN HOU

Co-Principal Investigator

  • MING YAO Division of General Internal Medicine
  • - - Division of General Internal Medicine
  • Wen-Chien Chou Division of General Internal Medicine
  • - - Division of General Internal Medicine
  • Chien-Chin Lin Division of General Internal Medicine
  • CHENG-HONG TSAI Division of General Internal Medicine
  • 田豐銘 Division of General Internal Medicine
  • SHAN-CHI YU Division of General Internal Medicine

The Actual Total Number of Participants Enrolled

0 Recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

-

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    12 participants

  • Global

    140 participants